Alnylam Pharmace. buy Raymond James
Start price
30.07.25
/
50%
€295.00
Target price
30.07.26
€319.87
Performance (%)
14.61%
Price
23.12.25
€338.10
Summary
This prediction is currently active. The prediction currently has a performance of 14.61%. This prediction currently runs until 30.07.26. The prediction end date can be changed by Raymond_James at any time. Raymond_James has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | 1.593% | 1.593% |
| iShares Core DAX® | 0.765% | 4.791% |
| iShares Nasdaq 100 | 1.418% | 3.133% |
| iShares Nikkei 225® | 0.658% | 0.972% |
| iShares S&P 500 | 1.310% | 2.279% |
Comments by Raymond_James for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is now covered by analysts at Raymond James Financial, Inc.. They set an "outperform" rating and a $370.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by Raymond_James for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€254.50
01.11.24
01.11.24
€274.85
01.11.25
01.11.25
54.18%
02.11.25
02.11.25
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€247.40
02.08.24
02.08.24
€251.93
02.08.25
02.08.25
38.64%
03.08.25
03.08.25